Paul Swanson, MD
Hematology & Oncology · Port St Lucie, FLNPI 1861448243
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,223 and has fallen 87.2% since, to $285 in 2025. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 219 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$731
- Amgen$415
- Merck$260
- Pfizer$232
- AbbVie$228
- AstraZeneca$222
- plus $2K from 29 others
Across 39 payments — averaging $3177.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$115K
- Eli Lilly$9K
What the payments were for
- Food & beverage$3,58097%
- Education$953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 41 | $731 |
| Amgen | 25 | $415 |
| Merck | 15 | $260 |
| Pfizer | 19 | $232 |
| AbbVie | 12 | $228 |
| AstraZeneca(2 entities) | 13 | $222 |
| Novartis | 12 | $180 |
| Gilead(2 entities) | 8 | $142 |
| E.r. Squibb & Sons, L.L.C. | 10 | $122 |
| Incyte Corporation | 5 | $99 |
| Lilly USA, LLC | 5 | $92 |
| GSK | 4 | $88 |
| Astellas Pharma US Inc | 5 | $83 |
| Genentech USA, Inc. | 6 | $78 |
| Bristol Myers Squibb | 2 | $57 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Boehringer Ingelheim | 3 | $45 |
| Aurobindo Pharma USA, Inc. | 3 | $41 |
| Sanofi | 2 | $39 |
| Eisai Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Bayer | 2 | $36 |
| Tesaro, Inc. | 2 | $35 |
| Verastem, Inc. | 2 | $34 |
| Advanced Accelerator Applications | 2 | $34 |
| Karyopharm Therapeutics Inc. | 1 | $31 |
| Puma Biotechnology, Inc. | 2 | $30 |
| Rigel Pharmaceuticals, Inc. | 2 | $30 |
| Dova Pharmaceuticals | 2 | $30 |
| Seagen Inc. | 2 | $28 |
| Grifols USA, LLC | 2 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Coherus Oncology, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
How this compares
$3,675 in reported general payments places this provider in the 45th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 59 | $828,366 |
| Lenalidomide | 39 | $464,440 |
| ImbruvicaIbrutinib | 44 | $390,192 |
| Lupron DepotLeuprolide Acetate | 34 | $263,338 |
| RituxanRituximab | 13 | $237,445 |
| IbrancePalbociclib | 12 | $180,281 |
| BivigamImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $144,987 |
| CalquenceAcalabrutinib Maleate | 12 | $98,618 |
| EliquisApixaban | 91 | $69,270 |
| Abiraterone Acetate | 44 | $46,803 |
| XgevaDenosumab | 11 | $35,872 |
| Imatinib Mesylate | 22 | $25,205 |
| Aprepitant | 15 | $4,596 |
| Anagrelide Hcl | 14 | $2,381 |
| Hydroxyurea | 88 | $2,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $83 | $828,36659 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $15 | $390,19244 claims |
| AbbVieLupron Depot | $228 | $263,33834 claims |
| PfizerIbrance, Eliquis | $232 | $249,551103 claims |
| AstraZenecaCalquence | $222 | $98,61812 claims |
| AmgenXgeva | $415 | $35,87211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Port St Lucie
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.